Colistin and Rifampicin Compared With Colistin Alone for the Treatment of Serious Infections Due to Extensively Drug-Resistant Acinetobacter baumannii: A Multicenter, Randomized Clinical Trial

粘菌素 鲍曼不动杆菌 医学 利福平 药品 抗生素 抗药性 临床试验 重症监护医学 内科学 药理学 微生物学 细菌 铜绿假单胞菌 生物 肺结核 病理 遗传学
作者
Emanuele Durante‐Mangoni,Giuseppe Signoriello,Roberto Andini,Annunziata Mattei,Maria De Cristoforo,Patrizia Murino,Matteo Bassetti,Paolo Malacarne,Nicola Petrosillo,Nicola Galdieri,Paola Elvira Mocavero,Antonio Corcione,Claudio Viscoli,Raffaele Zarrilli,Ciro Gallo,Riccardo Utili
出处
期刊:Clinical Infectious Diseases [Oxford University Press]
卷期号:57 (3): 349-358 被引量:434
标识
DOI:10.1093/cid/cit253
摘要

BACKGROUND: Extensively drug-resistant (XDR) Acinetobacter baumannii may cause serious infections in critically ill patients. Colistin often remains the only therapeutic option. Addition of rifampicin to colistin may be synergistic in vitro. In this study, we assessed whether the combination of colistin and rifampicin reduced the mortality of XDR A. baumannii infections compared to colistin alone. METHODS: This multicenter, parallel, randomized, open-label clinical trial enrolled 210 patients with life-threatening infections due to XDR A. baumannii from intensive care units of 5 tertiary care hospitals. Patients were randomly allocated (1:1) to either colistin alone, 2 MU every 8 hours intravenously, or colistin (as above), plus rifampicin 600 mg every 12 hours intravenously. The primary end point was overall 30-day mortality. Secondary end points were infection-related death, microbiologic eradication, and hospitalization length. RESULTS: Death within 30 days from randomization occurred in 90 (43%) subjects, without difference between treatment arms (P = .95). This was confirmed by multivariable analysis (odds ratio, 0.88 [95% confidence interval, .46-1.69], P = .71). A significant increase of microbiologic eradication rate was observed in the colistin plus rifampicin arm (P = .034). No difference was observed for infection-related death and length of hospitalization. CONCLUSIONS: In serious XDR A. baumannii infections, 30-day mortality is not reduced by addition of rifampicin to colistin. These results indicate that, at present, rifampicin should not be routinely combined with colistin in clinical practice. The increased rate of A. baumannii eradication with combination treatment could still imply a clinical benefit. CLINICAL TRIALS REGISTRATION: NCT01577862.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
星辰大海的应助被YXH采纳,获得10
1秒前
gaoyi12356发布了新的文献求助10
2秒前
Ava的应助被鹤立名堂采纳,获得10
2秒前
朱古力发布了新的文献求助10
2秒前
2秒前
丘比特的应助被猪猪猪采纳,获得10
2秒前
3秒前
Mars完成签到,获得积分10
3秒前
3秒前
3秒前
经竺的应助被车厘子采纳,获得10
4秒前
科研顺利完成签到 ,获得积分10
4秒前
5秒前
黄毛虎发布了新的文献求助10
5秒前
luo完成签到,获得积分10
6秒前
Voyager发布了新的文献求助10
6秒前
luan完成签到,获得积分10
6秒前
7秒前
7秒前
banana的应助被爱笑的大白菜采纳,获得10
7秒前
8秒前
求文献完成签到,获得积分10
8秒前
8秒前
8秒前
zzzz发布了新的文献求助10
8秒前
8秒前
9秒前
9秒前
lujiajia发布了新的文献求助10
10秒前
10秒前
10秒前
10秒前
11秒前
Jellykeke完成签到,获得积分10
11秒前
Wenyilong发布了新的文献求助10
12秒前
crity发布了新的文献求助20
13秒前
吱吱发布了新的文献求助10
13秒前
沉默小玉发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187480
求助须知:如何正确求助?哪些是违规求助? 9575554
关于积分的说明 21841909
捐赠科研通 7785230
什么是DOI,文献DOI怎么找? 3434949
关于科研通互助平台的介绍 2559412
邀请新用户注册赠送积分活动 2481898